샘플 요청 목록

 카트 문의
시장보고서
상품코드
1737292

세계의 신경변성 치료제 시장

Neurodegenerative Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 376 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

신경변성 치료제 세계 시장은 2030년까지 649억 달러에 달할 전망

2024년에 437억 달러로 추정되는 신경변성 치료제 세계 시장은 분석 기간인 2024-2030년에 CAGR 6.8%로 성장하여 2030년에는 649억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 도파민 작용제는 CAGR 8.3%를 기록하며 분석 기간 종료시에는 257억 달러에 달할 것으로 예상됩니다. 탈탄산효소 억제제 부문의 성장률은 분석 기간 동안 CAGR 7.6%로 추정됩니다.

미국 시장은 119억 달러로 추정, 중국은 CAGR 10.9%로 성장 예측

미국의 신경변성 치료제 시장은 2024년에는 119억 달러에 달할 것으로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 137억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 10.9%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 3.3%와 6.7%로 예측됩니다. 유럽에서는 독일이 CAGR 4.5%로 성장할 것으로 예측됩니다.

세계의 신경변성 치료제 시장 - 주요 동향과 촉진요인 정리

신경변성 치료제 개발이 임상적, 상업적으로 다시 주목받는 이유는 무엇일까?

알츠하이머병, 파킨슨병, 근위축성측색경화증(ALS), 헌팅턴병, 다계통위축증과 같은 신경변성은 전 세계 의료계의 가장 시급하고 복잡한 과제 중 하나입니다. 이들 질환은 진행성 신경세포의 퇴화를 동반하며, 그 결과 인지, 운동, 행동 장애를 유발하고 시간이 지남에 따라 악화되지만 거의 완치되지 않습니다. 전 세계적으로 고령화가 진행됨에 따라 이러한 질환의 발병률은 급격히 증가하고 있으며, 의료 시스템과 간병인에게 큰 부담을 주고 있습니다. 그 결과, 신경변성 치료제 시장은 제약회사, 생명공학 기업, 공중보건 기관들의 관심이 급증하고 있습니다.

역사적으로 신경변성 치료제 파이프라인은 높은 금단현상, 제한된 효능, 안전성 문제로 어려움을 겪어왔습니다. 그러나 유전학, 단백질 오폴딩 연구, 신경면역학의 비약적인 발전으로 현재는 증상 치료가 아닌 근본적인 병태생리를 타겟으로 하는 질병 변형 치료제(DMT)의 개발이 진행되고 있습니다. 정부의 우대 조치, 패스트 트랙 지정, 민관 연구 이니셔티브 등 기술 혁신에 유리한 생태계가 구축되고 있습니다. 신경변성의 사회적, 경제적 부담이 증가함에 따라, 의약품 개발자들은 의학적 중요성뿐만 아니라 막대한 미충족 시장 잠재력 때문에 이 치료 영역을 우선순위에 두고 있습니다.

질병 변형 접근법과 새로운 메커니즘은 신경변성 치료제의 미래를 어떻게 형성할 것인가?

최근 질병 생물학의 흐름은 약물 개발의 초점을 대증요법에서 질병 변형적 개입으로 전환하고 있습니다. 알츠하이머병에서는 베타 아밀로이드(아두카누맙, 레카네맙 등)와 타우 단백질을 표적으로 하는 단클론항체가 임상 평가 중이며, 조건부 승인을 받았습니다. 파킨슨병에서는 알파시누클레인을 표적으로 하는 면역요법, LRRK2 억제제, 도파민 수용체 작용제가 도파민성 신경세포의 감소를 늦추기 위해 연구되고 있습니다. 유전자 치료, RNA 표적 약물(안티센스 올리고뉴클레오티드 등), 신경영양인자 조절제 또한 여러 병태에서 시험 중입니다.

신경염증, 미토콘드리아 기능장애, 단백질 응집, 산화스트레스를 표적으로 하는 저분자는 치료 기전의 폭을 넓히고 있습니다. 또한, 종양학 및 면역학에서 재사용된 약물이 신경변성의 후기 임상시험에 진입하고 있습니다. 바이오마커 기반 환자 선택, 디지털 페노타이핑, 수액 바이오마커(예 : 수액 뉴로필라멘트 경쇄 등)의 사용은 임상시험의 효율성과 치료의 개별화를 향상시키고 있습니다. 이러한 혁신은 완화에서 질병 경과에 대한 잠재적 변화로의 중요한 전환을 의미하며, 치료에 대한 기대와 규제 경로에 새로운 선례를 제시하고 있습니다.

신경변성 치료제 수요를 주도하는 환자군과 세계 지역은?

신경변성 치료제의 주요 환자군은 65세 이상의 노인, 특히 알츠하이머병과 파킨슨병에 가장 많이 걸리는 코호트를 대표하는 65세 이상입니다. 조기 발병자 및 유전적 소인을 가진 사람들도 유전체 스크리닝을 통해 확인되고 있으며, 보다 상세한 모니터링이 가능해져 조기 개입 전략이 가능해졌습니다. 경도인지장애(MCI)와 전조 파킨슨병의 진단이 증가함에 따라 치료의 여지가 넓어지고 초기 단계의 치료제에 대한 수요가 증가하고 있습니다.

지리적으로 북미가 신경변성 치료제 시장을 독점하고 있는데, 이는 탄탄한 R&D 인프라, 높은 진단 보급률, 새로운 치료제의 조기 도입에 기인합니다. 유럽은 희귀 신경변성에 대한 강력한 규제 지원과 협력적인 치매 치료 이니셔티브에 힘입어 그 뒤를 잇고 있습니다. 아시아태평양은 특히 일본과 중국의 급속한 고령화와 신경학 연구에 대한 투자 증가로 인해 수요가 가속화되고 있으며, 아시아태평양이 성장의 최전선으로 부상하고 있습니다. 세계 인식 개선 캠페인, 간병인 지원 프로그램, 원격진료의 확대는 특히 자원이 부족한 지역에서 접근성과 순응도를 높이고 있습니다.

신경변성 치료제 시장의 장기적인 성장과 혁신의 원동력은?

신경변성 치료제 시장의 성장 원동력은 인구 변화, 신경과학의 발전, 뇌 건강에 대한 공공 및 민간 투자의 증가입니다. 고령화 사회는 조기 개입 전략과 장기적인 질병 관리 솔루션에 대한 자금 지원을 촉진하고 있습니다. 규제 당국은 고위험, 고위험 영역의 치료 혁신을 장려하기 위해 조기 심사 경로, 조건부 승인, 희귀질환 의약품에 대한 인센티브를 제공하고 있습니다. 한편, 벤처 캐피털 및 대형 제약사와의 제휴를 통해 새로운 작용기전을 가진 신경 분야 스타트업에 자금이 유입되고 있습니다.

디지털 바이오마커, AI를 통한 신약개발 지원, 환자 계층화 도구는 임상시험 결과를 개선하고 정밀한 신경치료를 가능하게 합니다. 리얼월드에비던스(RWE)와 시판 후 조사는 규제 당국의 결정을 지원하고 상환 전략에 정보를 제공하기 위해 사용되고 있습니다. 신경변성의 사회적 피해가 증가함에 따라 치료 접근법은 병용요법, 신경 회복 전략, 비침습적 신경 조절 등으로 확대되고 있습니다. 이러한 요인들을 종합해 볼 때, 신경변성 치료제는 향후 수십 년 동안 혁신, 투자, 헬스케어 혁신의 최전선에 서게 될 것으로 보입니다.

부문

약물 종류(도파민 작용제, 탈탄산효소 억제제, 콜린에스테라아제 억제제, 면역조절제, 기타 약물 종류), 적응증(파킨슨병, 알츠하이머병, 다발성 경화증, 기타 적응증), 유통 채널(병원 약국, 온라인 프로바이더, 드럭스토어·소매 약국)

조사 대상 기업 사례(총 34개사)

  • AbbVie Inc.
  • AC Immune SA
  • Acorda Therapeutics, Inc.
  • Alector, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amylyx Pharmaceuticals, Inc.
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • CervoMed Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • H. Lundbeck A/S
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 매출원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사하고 있습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월 : 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월 : 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석:

미국 <> 중국 <> 멕시코 <> 캐나다 <> EU <> 일본 <> 인도 <> 기타 176개국

업계 최고의 이코노미스트 : Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.06.12

Global Neurodegenerative Drugs Market to Reach US$64.9 Billion by 2030

The global market for Neurodegenerative Drugs estimated at US$43.7 Billion in the year 2024, is expected to reach US$64.9 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2024-2030. Dopamine Agonist, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$25.7 Billion by the end of the analysis period. Growth in the Decarboxylase Inhibitors segment is estimated at 7.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.9 Billion While China is Forecast to Grow at 10.9% CAGR

The Neurodegenerative Drugs market in the U.S. is estimated at US$11.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$13.7 Billion by the year 2030 trailing a CAGR of 10.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Neurodegenerative Drugs Market - Key Trends & Drivers Summarized

Why Is Drug Development for Neurodegenerative Diseases Receiving Renewed Clinical and Commercial Focus?

Neurodegenerative diseases-such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, and multiple system atrophy-represent one of the most urgent and complex challenges in global medicine. These disorders involve progressive neuronal degradation, resulting in cognitive, motor, and behavioral impairments that worsen over time and remain largely incurable. As aging populations rise globally, the incidence of these conditions is increasing dramatically, placing immense pressure on healthcare systems and caregivers. Consequently, the market for neurodegenerative drugs is witnessing a surge in interest from pharmaceutical companies, biotech firms, and public health institutions.

Historically, the drug pipeline for neurodegenerative disorders has been plagued by high attrition rates, limited efficacy, and safety concerns. However, breakthroughs in genetics, protein misfolding research, and neuroimmunology are now driving the development of disease-modifying therapies (DMTs) that target underlying pathophysiology rather than just symptomatic relief. Government incentives, fast-track designations, and public-private research initiatives are creating a favorable ecosystem for innovation. As the societal and economic burden of neurodegeneration escalates, drug developers are prioritizing this therapeutic area not only for its medical importance but also for its massive unmet market potential.

How Are Disease-Modifying Approaches and Novel Mechanisms Shaping the Future of Neurodegenerative Drug Therapies?

Recent advances in disease biology have shifted the focus of drug development from symptomatic management to disease-modifying interventions. For Alzheimer’s, monoclonal antibodies targeting beta-amyloid (e.g., aducanumab, lecanemab) and tau proteins are under clinical evaluation and conditional approvals. In Parkinson’s disease, alpha-synuclein-targeting immunotherapies, LRRK2 inhibitors, and dopamine receptor agonists are being studied to slow dopaminergic neuronal loss. Gene therapies, RNA-targeting drugs (like antisense oligonucleotides), and neurotrophic factor modulators are also being trialed across multiple conditions.

Small molecules targeting neuroinflammation, mitochondrial dysfunction, protein aggregation, and oxidative stress are expanding the scope of therapeutic mechanisms. Additionally, repurposed agents from oncology and immunology are entering late-stage trials in neurodegenerative settings. Biomarker-driven patient selection, digital phenotyping, and the use of fluid biomarkers (such as CSF neurofilament light chain) are improving trial efficiency and therapeutic personalization. These innovations mark a critical transition from palliation to potential alteration of disease trajectory, setting a new precedent for treatment expectations and regulatory pathways.

Which Patient Segments and Global Regions Are Driving Demand for Neurodegenerative Drugs?

The primary patient demographics for neurodegenerative drugs are older adults, especially those over 65, who represent the most affected cohort for Alzheimer’s and Parkinson’s. Early-onset and genetically predisposed populations are also being identified and monitored more closely through genomic screening, enabling earlier intervention strategies. The increasing diagnosis of mild cognitive impairment (MCI) and prodromal Parkinson’s is expanding the treatment window and driving demand for early-stage therapeutics.

Geographically, North America dominates the neurodegenerative drug market due to robust R&D infrastructure, high diagnostic penetration, and early adoption of novel therapeutics. Europe follows with strong regulatory support for rare neurodegenerative conditions and coordinated dementia care initiatives. Asia-Pacific is emerging as a growth frontier, particularly in Japan and China, where rapidly aging populations and increasing investment in neurological research are accelerating demand. Global awareness campaigns, caregiver support programs, and telemedicine expansion are facilitating access and adherence, especially in under-resourced regions.

What Is Fueling Long-Term Growth and Innovation in the Neurodegenerative Drugs Market?

The growth in the neurodegenerative drugs market is driven by demographic trends, advances in neuroscience, and increasing public and private investment in brain health. Aging societies are catalyzing funding for early intervention strategies and long-term disease management solutions. Regulatory bodies are offering accelerated review pathways, conditional approvals, and orphan drug incentives to encourage therapeutic innovation in high-risk, high-failure domains. Meanwhile, venture capital and big pharma partnerships are funneling resources into neurology startups with novel mechanisms of action.

Digital biomarkers, AI-assisted drug discovery, and patient stratification tools are improving trial outcomes and enabling precision neurotherapeutics. Real-world evidence (RWE) and post-market surveillance are being used to support regulatory decisions and inform reimbursement strategies. As the societal toll of neurodegeneration intensifies, therapeutic approaches are expanding to include combination regimens, neurorestorative strategies, and non-invasive neuromodulation. Collectively, these factors ensure that neurodegenerative drugs will remain at the forefront of innovation, investment, and healthcare transformation in the coming decades.

SCOPE OF STUDY:

The report analyzes the Neurodegenerative Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators, Other Drug Classes); Indication (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Other Indications); Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores & Retail Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbbVie Inc.
  • AC Immune SA
  • Acorda Therapeutics, Inc.
  • Alector, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amylyx Pharmaceuticals, Inc.
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • CervoMed Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • H. Lundbeck A/S
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Neurodegenerative Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Alzheimer's, Parkinson's, and ALS Propels Demand for Neurodegenerative Therapies
    • Expansion of Aging Global Population Strengthens Business Case for Long-Term CNS Treatments
    • Advancements in Amyloid and Tau-Targeting Drug Development Accelerate Clinical Trial Activity
    • Surge in Orphan Drug Approvals Throws the Spotlight on Rare Neurological Disorders
    • Increased Investment in CNS Drug Discovery Enhances Innovation in Neuroprotective Agents
    • Adoption of Biomarker-Guided Clinical Trials Supports Early Detection and Patient Stratification
    • Integration of AI in Neurodegenerative Drug Research Enables Faster Target Identification
    • Improved Understanding of Disease Pathophysiology Spurs Development of Disease-Modifying Therapies
    • Growth in Neurorehabilitation Support Programs Enhances Market Adoption Synergies
    • Rising Use of mRNA and Gene Therapies Expands Future Treatment Modalities
    • Emergence of Multimodal Drug Formulations Strengthens Combination Therapy Frameworks
    • Regulatory Incentives for Breakthrough Therapies Accelerate Pipeline Advancements
    • Challenges in CNS Drug Delivery and BBB Penetration Drive Nanotechnology-Based Innovation
    • Increased Focus on Real-World Evidence Collection Supports Post-Marketing Surveillance
    • Expansion of Collaborative Research Between Academia and Biopharma Enhances Portfolio Diversity
    • Growing Inclusion of Patient-Reported Outcomes Enhances Therapy Value Demonstration
    • Availability of Companion Diagnostics Boosts Personalization of Neurodegenerative Treatments
    • Societal and Economic Burden of Dementia Drives Policy-Level Attention and Funding
    • Uneven Access to Advanced Therapies Across Geographies Creates Global Disparities
    • Rise in Caregiver Support Ecosystems Supports Holistic Drug Adoption Pathways
    • Expansion of Digital Health Tools and Wearables Drives Remote Monitoring of Treatment Response
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Neurodegenerative Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Neurodegenerative Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Dopamine Agonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Dopamine Agonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Dopamine Agonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Decarboxylase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Decarboxylase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Decarboxylase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Cholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Cholinesterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Immunomodulators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Online Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Drug Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Parkinson's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Parkinson's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Parkinson's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Alzheimer's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Alzheimer's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Alzheimer's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Multiple Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • JAPAN
    • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • CHINA
    • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • EUROPE
    • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Neurodegenerative Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • FRANCE
    • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • GERMANY
    • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Neurodegenerative Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • INDIA
    • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Neurodegenerative Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Neurodegenerative Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
  • AFRICA
    • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제